


L1 HAS NO ANSWERS
L1 STR



VAR G1=O/S/N/C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

(FILE 'HOME' ENTERED AT 12:30:03 ON 15 JAN 2003)

FILE 'REGISTRY' ENTERED AT 12:30:11 ON 15 JAN 2003

L1 STRUC
L2 37 S L1
L3 815 S L1 FUL

FILE 'CAPLUS' ENTERED AT 12:32:01 ON 15 JAN 2003

L4 49 S L3

FILE 'REGISTRY' ENTERED AT 12:36:13 ON 15 JAN 2003



L5 STRUC
L6 447 SEARCH L5 SSS SUB=L3 FUL
L7 STRUC
L8 133 SEARCH L7 SSS SUB=L3 FUL

FILE 'CAPLUS' ENTERED AT 12:38:58 ON 15 JAN 2003

L9 4 S L8
L10 45 S L4 NOT L9
L11 37 S L10 AND P/DT
L12 12 S L11 AND PY<1999

AN 2000:535106 CAPLUS
 DN 133:150348
 TI Preparation of alkynyl containing hydroxamic acid compounds as TACE inhibitors
 IN Levin, Jeremy Ian; Venkatesan, Aranapakam Mudumbai; Cole, Derek Cecil; Chen, James Ming; Davis, Jamie Marie; Grosu, George Theodore
 PA American Cyanamid Company, USA
 SO PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000044713	A1	20000803	WO 2000-US2078	20000127
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1147080	A1	20011024	EP 2000-911652	20000127
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 2000007783	A	20020205	BR 2000-7783	20000127
	NO 2001003677	A	20010920	NO 2001-3677	20010726
PRAI	US 1999-239088	A	19990127		
	WO 2000-US2078	W	20000127		
OS	MARPAT 133:150348				
GI					



AB The title compds. [I; R1 = H, aryl, heteroaryl, etc.; R2, R3 = H, alkyl, CN, CCH; R8-R11 = H, aryl, aralkyl, etc.; R12 = H, aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S, O, etc.; A = O, S, SO, etc.; X = O, S, SO, etc.; Y = aryl, heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; n = 0-2] and their pharmaceutically acceptable salts, useful in treating disease conditions mediated by TNF-.alpha., such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss, were prepd. E.g., a multi-step synthesis of II.HCl which showed IC50 of 191 nM against TACE, and IC50 of 2 nM, 180 nM, and 200 nM against MMP-1, MMP-9, and MMP-13, resp., was given.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

IT 287391-48-4P 287392-15-8P 287392-16-9P
287392-19-2P 287392-25-0P 287392-26-1P
287392-30-7P 287392-31-8P 287392-32-9P
287392-34-1P 287392-35-2P 287392-37-4P
287392-42-1P 287392-44-3P 287392-46-5P
287392-50-1P 287392-54-5P 287392-57-8P
287392-60-3P 287392-66-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of alkynyl contg. hydroxamic acid compds. as TACE inhibitors)


RN 287391-48-4 CAPLUS

CN Octanamide, 2-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-15-8 CAPLUS

CN Cyclohexaneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-16-9 CAPLUS

CN Cyclohexaneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-19-2 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)




RN 287392-25-0 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-4-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-26-1 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-4-chloro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-30-7 CAPLUS


CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-31-8 CAPLUS

CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287392-32-9 CAPLUS


CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-34-1 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy-4-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 287392-35-2 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-4-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 287392-37-4 CAPLUS

CN 1-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-42-1 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)




RN 287392-44-3 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-4-ethoxy-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-46-5 CAPLUS

CN Benzeneacetamide, 3-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-50-1 CAPLUS

CN Butanamide, 2-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 287392-54-5 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI)
(CA INDEX NAME)




RN 287392-57-8 CAPLUS

CN 2-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI)
(CA INDEX NAME)




RN 287392-60-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[[4-(2-butynyloxy)phenyl]sulfonyl]-2-(hydroxyamino)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 287392-66-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI)
(CA INDEX NAME)




IT 287391-43-9P 287391-44-0P 287391-45-1P
 287391-46-2P 287391-47-3P 287391-49-5P
 287391-50-8P 287391-53-1P 287391-55-3P
 287391-56-4P 287391-57-5P 287391-58-6P
 287391-59-7P 287391-60-0P 287391-61-1P
 287391-62-2P 287391-63-3P 287391-64-4P
 287391-65-5P 287391-66-6P 287391-67-7P
 287391-68-8P 287391-69-9P 287391-70-2P
 287391-71-3P 287391-72-4P 287391-73-5P
 287391-74-6P 287391-75-7P 287391-76-8P
 287391-77-9P 287391-78-0P 287391-79-1P
 287391-80-4P 287391-81-5P 287391-82-6P
 287391-83-7P 287391-84-8P 287391-85-9P
 287391-86-0P 287391-87-1P 287391-88-2P
 287391-89-3P 287391-90-6P 287391-91-7P
 287391-92-8P 287391-93-9P 287391-94-0P
 287391-95-1P 287391-96-2P 287391-97-3P
 287391-98-4P 287391-99-5P 287392-00-1P
 287392-01-2P 287392-02-3P 287392-03-4P
 287392-04-5P 287392-05-6P 287392-06-7P
 287392-07-8P 287392-08-9P 287392-09-0P
 287392-10-3P 287392-11-4P 287392-12-5P
 287392-13-6P 287392-14-7P 287392-17-0P
 287392-21-6P 287392-22-7P 287392-24-9P
 287392-27-2P 287392-28-3P 287392-29-4P
 287392-33-0P 287392-36-3P 287392-38-5P
 287392-39-6P 287392-40-9P 287392-41-0P
 287392-43-2P 287392-45-4P 287392-47-6P
 287392-48-7P 287392-49-8P 287392-51-2P
 287392-52-3P 287392-53-4P 287392-55-6P
 287392-56-7P 287392-58-9P 287392-59-0P
 287392-61-4P 287392-62-5P 287392-63-6P
 287392-64-7P 287392-65-8P 287392-67-0P
 287392-68-1P 287393-60-6P 287393-61-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of alkynyl contg. hydroxamic acid compds. as TACE inhibitors)


RN 287391-43-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-4-[2-(1-piperidinyloxy)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287391-44-0 CAPLUS
 CN [1,1'-Biphenyl]-4-propanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 287391-45-1 CAPLUS
 CN 3-Pyridinepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287391-46-2 CAPLUS
 CN Propanamide, 2-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287391-47-3 CAPLUS
 CN Octanamide, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 287391-49-5 CAPLUS

CN Octanamide, 2-[(R)-[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287391-50-8 CAPLUS


CN Octanamide, 2-[(S)-[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287391-53-1 CAPLUS

CN Acetamide, 2-[4-(2-butynyloxy)phenoxy]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287391-55-3 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 287391-56-4 CAPLUS

CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-57-5 CAPLUS

CN Benzamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-58-6 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 287391-59-7 CAPLUS


CN 3-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-60-0 CAPLUS
 CN 2-Thiophenebutanamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-61-1 CAPLUS
 CN 9H-Xanthene-9-carboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)



RN 287391-62-2 CAPLUS
 CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287391-63-3 CAPLUS
 CN 1-Isoquinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-64-4 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-(9CI) (CA INDEX NAME)




RN 287391-65-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-(9CI) (CA INDEX NAME)




RN 287391-66-6 CAPLUS


CN 2H-Isoindole-2-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-1,3-dihydro-1,3-dioxo-(9CI) (CA INDEX NAME)




RN 287391-67-7 CAPLUS
 CN Benzamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-68-8 CAPLUS
 CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 287391-69-9 CAPLUS
 CN 3-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)



RN 287391-70-2 CAPLUS
 CN 2-Thiophenebutanamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-71-3 CAPLUS
 CN 9H-Xanthene-9-carboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-72-4 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287391-73-5 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-74-6 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-75-7 CAPLUS

CN 1H-Indole-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-76-8 CAPLUS

CN Benzamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-77-9 CAPLUS

CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-78-0 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 287391-79-1 CAPLUS

CN Benzeneacetamide, N- [5- [[4- (2-butynyloxy)phenyl]sulfonyl] -6- (hydroxyamino) -6-oxohexyl] -3,4-dichloro- (9CI) (CA INDEX NAME)




RN 287391-80-4 CAPLUS


CN 3-Quinolinecarboxamide, N- [5- [[4- (2-butynyloxy)phenyl]sulfonyl] -6- (hydroxyamino) -6-oxohexyl] - (9CI) (CA INDEX NAME)



RN 287391-81-5 CAPLUS


CN 9H-Xanthene-9-carboxamide, N- [5- [[4- (2-butynyloxy)phenyl]sulfonyl] -6- (hydroxyamino) -6-oxohexyl] - (9CI) (CA INDEX NAME)






RN 287391-82-6 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287391-83-7 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-84-8 CAPLUS
 CN Benzo[b]thiophene-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-85-9 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 287391-86-0 CAPLUS
 CN 2-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

$\equiv \text{C-Me}$


RN 287391-87-1 CAPLUS
 CN 2H-Isoindole-2-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI)

(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 287391-88-2 CAPLUS


CN Benzamide, N-[2-[[5-[[4-(2-butyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-89-3 CAPLUS

CN 3-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B




RN 287391-90-6 CAPLUS



CN 9H-Xanthene-9-carboxamide, N-[2-[[5-[[4-(2-butyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 287391-91-7 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287391-92-8 CAPLUS
 CN 1-Isoquinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 287391-93-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 287391-94-0 CAPLUS


CN Benzo[b]thiophene-3-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 1-B




RN 287391-95-1 CAPLUS

CN 3-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287391-96-2 CAPLUS

CN 2-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287391-97-3 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 287391-98-4 CAPLUS


CN Benzamide, N-[2-[[5-[[4-(2-butyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-99-5 CAPLUS

CN Benzeneacetamide, N-[2-[[5-[[4-(2-butyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 287392-00-1 CAPLUS

CN 2-Thiophenebutanamide, N-[2-[[5-[[4-(2-butyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


≡C-Me

RN 287392-01-2 CAPLUS
 CN 9H-Xanthene-9-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 287392-02-3 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-.alpha.-phenyl- (9CI) (CA


INDEX NAME)



RN 287392-03-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 287392-04-5 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)



RN 287392-05-6 CAPLUS
 CN 2H-Isoindole-2-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A







RN 287392-06-7 CAPLUS

CN Benzamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287392-07-8 CAPLUS

CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)





RN 287392-08-9 CAPLUS

CN 3-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)





$\equiv \text{C}-\text{Me}$

RN 287392-09-0 CAPLUS
 CN 9H-Xanthene-9-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)





RN 287392-10-3 CAPLUS
 CN 1-Isoquinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 287392-11-4 CAPLUS


CN Benzo[b]thiophene-3-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 287392-12-5 CAPLUS

CN 1H-Indole-3-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287392-13-6 CAPLUS

CN Benzenebutanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-4-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287392-14-7 CAPLUS

CN Heptanamide, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]-7-cyano-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-17-0 CAPLUS


CN Cyclohexaneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-21-6 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-4-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287392-22-7 CAPLUS


CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-4-methoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-24-9 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)




RN 287392-27-2 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-4-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-28-3 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-3-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-29-4 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-3-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-33-0 CAPLUS

CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-36-3 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-4-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 287392-38-5 CAPLUS

CN 1-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-39-6 CAPLUS

CN 1-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-40-9 CAPLUS


CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-41-0 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-43-2 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)




RN 287392-45-4 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-4-ethoxy-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-47-6 CAPLUS
 CN Benzeneacetamide, 3-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-48-7 CAPLUS
 CN Benzeneacetamide, 3-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-49-8 CAPLUS
 CN Benzeneacetamide, 3-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-51-2 CAPLUS
 CN Butanamide, 2-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-52-3 CAPLUS
 CN Butanamide, 2-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287392-53-4 CAPLUS


CN Butanamide, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-3-methyl- (9CI)
(CA INDEX NAME)



RN 287392-55-6 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-,
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287392-56-7 CAPLUS


CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-,
(.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-58-9 CAPLUS

CN 2-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-59-0 CAPLUS

CN 2-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-61-4 CAPLUS

CN 4-Piperidineacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-62-5 CAPLUS

CN 4-Piperidineacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-1-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 287392-63-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-64-7 CAPLUS

CN 4-Piperidineacetamide, 1-acetyl-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-65-8 CAPLUS

CN 2H-Pyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-67-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-, 1-oxide (9CI) (CA INDEX NAME)




RN 287392-68-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 287393-60-6 CAPLUS

CN 3-Pyridinepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 287393-61-7 CAPLUS

CN Benzenepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-4-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




IT 287391-65-5D, resin-supported 287391-76-8D, resin-supported 287391-85-9D, resin-supported 287391-95-1D, resin-supported 287392-04-5D, resin-supported 287393-58-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of alkynyl contg. hydroxamic acid compds. as TACE inhibitors)


RN 287391-65-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 287391-76-8 CAPLUS


CN Benzenepropanamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-85-9 CAPLUS

CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 287391-95-1 CAPLUS

CN 3-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

≡C-Me


RN 287392-04-5 CAPLUS

CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)



RN 287393-58-2 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-3-chloro-N-hydroxy- (9CI) (CA INDEX NAME)



IT 287393-26-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of alkynyl contg. hydroxamic acid compds. as TACE inhibitors)

RN 287393-26-4 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)

